Adjunctive Medical Therapy with Oral Silodosin after Shock Wave Lithotripsy of Lower Ureteral Stone: A randomized controlled study

The efficacy of adjunctive medical therapy with daily oral silodosin(4 mg) after Shock Wave Lithotripsy of lower ureteral stone

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000573954

Enrollment

Registered

2011-06-03

Start date

2010-06-01

Completion date

2011-12-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

a prospective study to evaluate the efficacy of oral silodosin 4 mg as adjunctive therapy after ESWL of lower ureteral stones

Interventions

Daily oral 4 mg silodosin for 2 weeks as adjunctive therapy after ESWL of lower ureteral stones

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Healthy volunteers

Inclusion criteria

Stones were calculated according to the diameter along the ureteral axis, and the size was between 4mm and 9 mm. All patients underwent ESWL were enrolled in the study after providing informed consent.

Exclusion criteria

urinary tract infections, high-grade hydronephrosis, diabetes, ulcers, or a history of hypersensitivity to a-blockers, ureteral stricture and pregnant women,history of spontaneous stone expulsion, hypotension, or those found to have systolic blood pressure lower than 110 mmHg

Outcome results